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Background: We intended to investigate the long-term clinical characteristics, responses to therapy and survival in
patients with lightchain multiple myeloma (MM).
Methods: Ninety-six patients were enrolled into the study. There were 42 κ-chain MM patients and 54 λ-chain MM
patients. All the patients werestage III in the Durie-Salmonstaging system. Among them, 66 patients received
Velcade (bortezomib) treatment and the other 30 did not.
Results: The main symptoms of these patients included bone pain (77.1%), weakness and fatigue (12.5%), foamy
urine (8.3%) and extramedullaryplasmocytomas (33.3%). The overall response rate (ORR) was 95.5% in patients
treated with Velcade and 60%in the patients without. The median survival times were 23 months in patients
treated with Velcade and 12 months in patients without. The median time of progression-free survival (PFS) was
nine months in patients treated with Velcade and five months in patients without. The one-year PFS and two-year
PFS were 37% and 25%, 27% and 9% for patients treated with Velcade, or without, respectively. The three-year
overall survival (OS) and five-year OS were 33% and 24%, 28% and 9% for patients treated with Velcade, or without,
respectively. There was no significance in OS between the two groups (P = 0.335). But there was significant
difference in PFS between the two groups (P = 0.036).
Conclusions: Our long-term study demonstrated that patients with lightchain myeloma appeared to have more
aggressive disease courses and poor outcomes, which could be improved by treatment with Velcade.
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Multiple myeloma (MM), a malignant lymphoproliferative
B-cell disease characterized by the accumulation of mono-
clonal plasma cells in the bone marrow, is the second
most frequent hematological malignancy [1,2]. The most
common type of M-protein found in MM is immuno-
globulin (Ig)G followed by IgA and light chain only. An
exclusive production of light chains can be found in 15%
of myeloma cases. Renal failure, bone disease and amyl-
oidosis appear to be more frequent in these patients.* Correspondence: xinli562@yahoo.com
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unless otherwise stated.Lightchain multiple myeloma also appears to have a
poorer prognosis than IgG and IgA subtypes when treated
with chemotherapy. However, the outcomes in the light
chain subtype have not been addressed specifically.
Velcade (bortezomib) is a first-in-class proteasome in-
hibitor, initially approved by the US Food and Drug Ad-
ministration (FDA) and the European Agency for the
Evaluation of Medicinal Products (EMEA) for patients
with relapsed and refractory MM who have received at
least two prior lines of therapy and progressed onto their
last therapy [3,4]. In the present study, we conducted a
long-term study (eightyears) to report the clinical char-
acteristics, responses to therapy and survival in patients
with light chain MM while they were either treated with
Velcade or not.Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Table 1 The characteristics of 96 light chain multiple myeloma patients
Characteristics With Velcade group(n = 66) Without Velcade group(n = 30) Total P value
Age(years) 59(28–86) 58(43–77) 58(28–86) >0.05
Sex(male/female) 34/29 17/16 51/45 >0.05
Albumin(g/L) 33.7(24.1-43.2) 32.1(17–42.4) 33.2(17–43.2) >0.05
Leucocyte(X109/L) 5.4(1.0-11.7) 4.4(1.5-8.3) 5.1(1.0-11.7) >0.05
Hemoglobin(g/L) 95.3(43–139) 99.3(51–140) 96.5(43–140) >0.05
Platelet(X109/L) 189(33–389) 180(34–513) 186(33–513) >0.05
C-reactive protein(mg/L) 12.76(0.62-60) 16.71(5.0-80) 13.89(0.62-80) >0.05
Sedimentation(mm/h) 52(1.0-170) 53(2–140) 52(1–170) >0.05
B2-microglobulin(mg/L) 7.51(1.06-38.15) 9.01(0.89-41.5) 7.96(0.89-41.5) >0.05
Bone marrow plasmacytosis(%) 34.7(0.5-84) 40.2(3.5-95) 36.4(0.5-95) >0.05
Lactate dehydrogenase(U/L) 179.5(91–849) 179.4(112–256) 179.5(91–849) >0.05
Uric acid(umol/L) 346(130–590) 344(128–517) 345(128–590) >0.05
Serum creatinine(umol/L) 177.3 (21.7-724.2) 108.5(31.27-507) 157.4(21.7-724.2) >0.05
Light chain(g/24 hour) 23.9(1.0-128.8) 23.4(1.2-89.0) 23.8(1.2-128.8) >0.05
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Patients
Ninety-six cases of light chains multiple myeloma at
Beijing Chao Yang Hospital and the Second Artillery
General Hospital deriving from a series of 459 symptom-
atic patients with MM were included into this study from
June 2005 to December 2012. There were 51 men and 45
women. The median age was 58 years (range, 28 to
86 years), and all these patients were accorded with mul-
tiple myeloma diagnostic criteria 1. These patients were
staged according to International Staging System (ISS)
and Durie-Salmon (DSS) staging system. Extramedullary-
plasmocytomas were examined by magnetic resonance
imaging (MRI) or computed tomography (CT), or were
identified by the treatment effect pathology criterion with
reference to the International Myeloma Working Group
(IMWG).
Clinical examination
For the examination of treatment responses, progression-
free survival (PFS) and overall survival (OS), the patients
were divided into two groups, the Velcade group (66
cases) and the without Velcade group (30 cases). For pa-
tients in the Velcade group, Velcade (1.0 mg/m2) and
dexamethasone (20 mg) were given at days 1, 4, 8, 11. For
patients without Velcade, they were given melphalanTable 2 Clinical type of 96 light chain multiple
myeloma patients
Group type κ λ (κ/λ)
Velcade group(n = 66) 28 38 28/38
Without Velcade group(n = 30) 14 16 14/16
Total 42 54 42/548 mg/m2 and prednisone 60 mg/m2(MP)orally between
days 1 and 4. Vinblastine 1.2 mg/m2 (M2) and simustine
20 mg/m2 (Me-CCUN) were given only at day 1. Also,
vinblastine 0.4 mg days 1 to 4, epirubicin 10 mg days 1
to4, dexamethasone 20 mg (VAD) at days 1 to 4, 9 to12)
or ifosfamide 0.5 g days 1 to 4, dexamethasone 20 mg days
1 to4, thalidomide 100 mg (CTD) each night were admin-
istered. All the patients had completed at least four cycles
of Velcade or chemotherapy and had been evaluated for
response to therapy after four cycles of therapy.Statistical analysis
The Kaplan-Meier method was used to estimate the prob-
ability of progression-free survival (PFS) and overall sur-
vival (OS). The log-rank test was used to compare PFS
and OS durations among different groups. PFS was de-
fined as the time from complete remission (CR) to relapse
and progression, death from any cause, or censoring of
the data on the patients. OS is defined as the time from
registration to death or censoring of the data on the pa-
tients. For all other statistical analysis between Velcade
and non-Velcade groups, a Student’s ttest (SPSS version
11.0) was used. Statistical significance was determined if
P < 0.05.Table 3 Durie-Salmon and International Staging System
(ISS) staging of 96 light chain multiple myeloma patients
Group subtype Durie-Salmon staging ISS staging
IIIA IIIB I II III
Velcade group(n = 66) 36 30 9 17 40
Without Velcade group(n = 30) 24 6 3 9 18
Total 60 36 12 26 58
Table 4 The symptoms of 96 multiple myeloma patients







Weakness and fatigue 10 2 12
Bone pain 51 23 74
Foam urine 4 4 8
Extramedullaryplasmocytomas 1 1 2
Figure 1 Comparing overall survival (OS) of the light chain
multiple myeloma patients in the Velcade group and the group
without Velcade (P = 0.335).
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Clinical characteristics of patients
Ninety-six patients were involved in this study, including
42 κ-chain MM patients and 54 λ-chain MM patients.
The basic characteristics of the patients had no signifi-
cance with the two groups (Tables 1 and 2). All the pa-
tients were stage III (DS), including 60 cases of IIIa
(62.5%) and 36 cases of IIIb (37.5%). There were 12
(12.5%) patients with stage I, 26(27.1%) patients with stage
II, 58 (60.4%) patients with stage III according to ISS sta-
ging (Table 3). There were 36/96 (37.5%) patients who
had renal failure at the initial onset of the disease and 99/
369 (27.5%) patients had renal failure of other type MM,
including IgG, IgA and IgD. According to the National
Kidney Foundation Practice Guidelines for Chronic Kid-
ney Disease [5], there were 17 patients at stage 2, 12 pa-
tients at stage 3, three patients at stage 4 and four
patients at stage 5. The initial symptoms included bone
pain in 74cases (77.1%), weakness in 12 cases (12.5%),
foamy urine ineight cases (8.3%), extramedullaryplasmo-
cytomas in two cases (2.1%) (Table 4). During the disease
progression, there were 78 (81.3%) patients had more than
three areas of bone destruction, 26 (27.1%) patients
complicated with pleural effusion, 32 (33.3%) patients com-
plicated with extramedullaryplasmocytomas, 36 (37.5%)
patients complicated with anemia, four (4.2%) patients
complicated with hypercalcemia, one patient progressed
into plasma cell leukemia and one patient complicated with
M protein and skin changes (POEMS) syndrome.
Response analysis
After four cycles of treatment, the response to therapy for
96 patients were evaluated. The ORR was 95.5% (63/66),














Velcade group (n = 66) 37(56.1%) 26(39.4%) 2(3.0%) 1(1.5%)
Without Velcade group
(n = 30)
3(10%) 15(50%) 6(20%) 6(20%)remission (PR) for patients treated with Velcade. The
ORR was 60% (18/30) including 10% (3/30) CR and 50%
(15/30) PR for the patients without Velcade treatment
(Table 5).
Survival and prognosis
At the end of the follow-up on March 31, 2013, there
were 25 patients who had died in the Velcade group and
14 patients had died in the group without Velcade treat-
ment. The median time of survival was 23 (four to 89)
months in the Velcade group and 12 (four to 67) months
in the group without Velcade, respectively. The median
time of PFS were nine (three to 36) months for the
Velcade group and five (two to 25) months for the group
without Velcade, respectively. The three-year OS and
five-year OS were 33% and 24%, respectively for the Vel-
cade group, and were 28% and 9% for the group without
Velcade. The one-year PFS, two-year PFS and three-year
PFS were 37%, 25% and 8%, respectively for the Velcade
group. The one-year PFS and two-year PFS were 27%
and 9% for the group without Velcade. There was no
significance with OS between two groups (P = 0.335)
(Figure 1). However, there was significant difference inFigure 2 Comparing progression-free survival (PFS) of the light
chain multiple myelomapatients in the Velcade group and the
group without Velcade (P = 0.036).
Zhang et al. World Journal of Surgical Oncology 2014, 12:234 Page 4 of 4
http://www.wjso.com/content/12/1/234PFS between them (P = 0.036) (Figure 2). There were 13
patients who lived more than five years in the Velcade
group, and only two patients in the group without
Velcade. All the 36 patients with renal failure were
treated with Velcade. Twelve patients (70.6%) with stage
2 renal functionrecovered normal kidney function, three
patients (25%) with stage 3 recovered, three patients
with stage 4 and four patients with stage 5did not reco-
vernormal kidney function, and thus needed dialysis
treatment.
Discussion
In the present study, the clinical profiles of the 96 pa-
tients suggested that anemia, bone destruction, pleural
effusion,extramedullaryplasmocytomas and renal failure
were the most common features of light chain MM. We
demonstrated that 33.3% patients had extramedullary
disease, higher than the percentage reported in a previ-
ous study [6]. The difference might be explained by the
fact that lightchain MM patients in our study had a
high tendency of having concomitant extramedullary
diseases [7-10].
Conclusion
Overall, we found that in the patients treated with
Velcade, the ORR was 95.5% (63/66), including 56.1%
(37/66) CR and 39.4% (26/66) PR. This is significantly
higher than the ORR of 60% (18/30) in the patients
without Velcade treatment. These results are in line with
previous reports [11-13], and strongly suggest the bene-
ficial effect of Velcade on the long-term survival and
prognosis for patients with light chain MM.
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